DNA test to help kidney transplant patients switch to a single anti-rejection drug
Part of Kidney & urinary clinical trials.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a previous study called STU-2020-1339
- You must have no antibodies that might attack your donor kidney
- Your kidney function must be stable, with an eGFR over 40 mL/min for the past 3 months
- You cannot be pregnant or planning pregnancy
- You must not have significant liver problems or other major health conditions that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a blood test that may help monitor kidney transplant health by detecting signs of rejection earlier. It aims to see if using this blood test can lead to better long-term outcomes for transplant recipients.
This study tests whether a special blood test can help monitor your new kidney after transplant. It may help doctors spot problems earlier and improve kidney health.
This Phase 2 study looks at whether blood test “biomarkers” can guide safely changing anti-rejection medicines after an ABO-compatible kidney transplant. It may help some people reduce certain medicines while keeping the new kidney protected from rejection.
This trial is testing whether a simple blood test that looks for donor DNA can help doctors take better care of kidney transplant patients. It may help detect early signs of rejection and guide treatment decisions.
This study tests a blood test called GraftAssure that may help doctors detect if your body is rejecting your new kidney. By monitoring this, the test could help prevent kidney damage and improve transplant outcomes.
This study looks at how genes in the kidney change when the body might be rejecting the transplant. By studying these genes, doctors hope to find better ways to detect kidney rejection early and help keep the kidney healthy longer.
Hear when a new Kidney Transplant Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.